Jump to main content
Jump to site search

Issue 1, 2013
Previous Article Next Article

From natural product to marketed drug: the tiacumicin odyssey

Author affiliations

Abstract

Covering: 1975 to 2012

The first members of the tiacumicin family of antibiotics, encompassing more than 40 compounds, were isolated in 1975. Structurally, the core aglycon is an 18-membered macrolactone having two conjugated diene units, one isolated double bond, 5 stereogenic centers and most often, at least one glycosidic linkage. Tiacumicin B, a RNA synthesis inhibitor, is a narrow-spectrum antibiotic against clostridia. For the treatment of Clostridium difficile infection (CDI), it has the same cure rate as vancomycin but with lower relapse rate and was approved by the FDA in May 2011. The aim of this review is to present an overview of the chemistry and biology of tiacumicins since their discovery.

Graphical abstract: From natural product to marketed drug: the tiacumicin odyssey

Back to tab navigation

Article information


Submitted
24 Jul 2012
First published
30 Oct 2012

Nat. Prod. Rep., 2013,30, 161-174
Article type
Review Article

From natural product to marketed drug: the tiacumicin odyssey

W. Erb and J. Zhu, Nat. Prod. Rep., 2013, 30, 161
DOI: 10.1039/C2NP20080E

Social activity

Search articles by author

Spotlight

Advertisements